Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis
- PMID: 26866663
- DOI: 10.1016/j.leukres.2016.01.014
Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis
Abstract
Survival of acute myeloid leukemia (AML) patients, who are unfit for high-dose chemotherapy, has significantly improved with the advent of low-intensity therapeutic regimens (LITR, comprising decitabine, azacitidine, and low-dose cytarabine). However, infectious complications are common during LITR treatment and might hamper the beneficial effect of these drugs. In this study, we aimed to evaluate the incidence of and predisposing risk factors for infections during LITR treatment of AML, as well as the value of antibiotic prophylaxis within this setting. Therefore, we retrospectively analyzed 40 AML patients, treated with 215 cycles of LITR and analyzed putative risk factors by multivariate logistic regression. Infections occurred in 53/215 (25%) of LITR cycles, resulting in death in six patients. Of the parameters assessed at the start of each LITR cycle, transfusion dependence (p=0.008) and increased LDH (p=0.027) independently predicted the occurrence of infection. Most importantly, however, antibiotic prophylaxis was independently associated with a decreased rate of infectious complications (p=0.030). It was regularly performed in neutropenic patients and even managed to eliminate low neutrophil counts as risk factor in multivariate models. These data argue for the efficacy of antibiotic prophylaxis during LITR therapy of AML and suggest its further evaluation within a prospective clinical trial.
Keywords: Acute myeloid leukemia; Antibiotic prophylaxis; Infection; Low-intensity treatment regimen.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Similar articles
-
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.Cancer Med. 2017 Dec;6(12):2814-2821. doi: 10.1002/cam4.1231. Epub 2017 Oct 23. Cancer Med. 2017. PMID: 29058375 Free PMC article.
-
Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.Clin Lymphoma Myeloma Leuk. 2019 May;19(5):264-274.e4. doi: 10.1016/j.clml.2019.01.002. Epub 2019 Jan 23. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30898482
-
The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment.Ann Hematol. 2017 Nov;96(11):1833-1840. doi: 10.1007/s00277-017-3091-x. Epub 2017 Aug 13. Ann Hematol. 2017. PMID: 28803258
-
Decitabine. Acute myeloid leukaemia: no progress.Prescrire Int. 2014 Apr;23(148):92-4. Prescrire Int. 2014. PMID: 24860891 Review.
-
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.Leuk Res. 2015 Feb;39(2):183-91. doi: 10.1016/j.leukres.2014.11.027. Epub 2014 Dec 9. Leuk Res. 2015. PMID: 25577399 Review.
Cited by
-
No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine-a prospective multicenter study by the Polish Adult Leukemia Group.Front Oncol. 2024 Jun 13;14:1404322. doi: 10.3389/fonc.2024.1404322. eCollection 2024. Front Oncol. 2024. PMID: 38939343 Free PMC article.
-
Non-Coding RNAs: Uncharted Mediators of Thyroid Cancer Pathogenesis.Cancers (Basel). 2020 Nov 4;12(11):3264. doi: 10.3390/cancers12113264. Cancers (Basel). 2020. PMID: 33158279 Free PMC article. Review.
-
Noncoding RNAs in cancer therapy resistance and targeted drug development.J Hematol Oncol. 2019 Jun 7;12(1):55. doi: 10.1186/s13045-019-0748-z. J Hematol Oncol. 2019. PMID: 31174564 Free PMC article. Review.
-
Spectrum of infections in different regimens of post-induction chemotherapy in acute myeloid leukemia (de-novo): A comparative retrospective study.Heliyon. 2024 Jan 17;10(3):e24561. doi: 10.1016/j.heliyon.2024.e24561. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38317981 Free PMC article.
-
Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network.Cancers (Basel). 2022 Feb 6;14(3):826. doi: 10.3390/cancers14030826. Cancers (Basel). 2022. PMID: 35159092 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical